시장보고서
상품코드
2108261

차세대 시퀀싱 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 서비스, 기술, 구성 요소, 용도, 프로세스, 최종 사용자, 솔루션

Next Generation Sequencing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 6,519,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 7,892,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 9,265,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 시퀀싱 시장은 2025년 161억 달러에서 2035년까지 461억 달러로 성장하여 CAGR은 11.1%를 나타낼 것으로 예측됩니다. 차세대 시퀀싱 시장은 적당히 통합된 구조를 특징으로 하며, 임상 진단, 종양학, 신약 개발, 유전체 연구 분야의 채택 확대에 따라 시퀀싱 서비스 및 시퀀싱 플랫폼이 주요 부문을 차지하고 있습니다. 이 시장은 시퀀싱 비용의 감소, 기술 발전, 그리고 정밀 의학에 대한 수요 증가에 힘입어 성장하고 있습니다. 경쟁은 여전히 치열하며, 일루미나, 써모피셔 사이언티픽, BGI 그룹 등 주요 기업들은 혁신, 파트너십 및 포트폴리오 확대에 주력하고 있습니다. 예를 들어, 2025년 1월 일루미나는 엔비디아(NVIDIA)와의 제휴를 발표하며, 시퀀싱 기술과 AI 도구를 결합하여 멀티오믹스 데이터 분석 및 정밀 헬스 분야의 응용을 추진할 것이라고 밝혔습니다.

유형별로는 2025년 차세대 시퀀싱 시장에서 전체 유전체 염기서열 분석 부문이 주도적인 위치를 차지했습니다. 이는 생물의 전체 DNA 서열을 분석함으로써 종합적인 유전체 정보를 제공할 수 있기 때문입니다. 전장 유전체 시퀀싱은 고해상도 데이터를 생성할 수 있는 능력 덕분에 임상 연구, 희귀질환 진단, 정밀 의학, 종양학 연구 및 집단 유전체학 분야에서 널리 채택되고 있습니다. 이 부문은 시퀀싱 비용의 하락, 생물정보학 플랫폼의 개선, 그리고 대규모 유전체 이니셔티브에 대한 투자 증가의 혜택을 받고 있습니다. 유전적 변이 식별 및 맞춤형 치료 전략 지원을 목적으로 학술 기관, 제약 회사, 의료 서비스 제공업체 사이에서 채택이 확대되고 있는 것이 시장 내 선도적 지위를 더욱 공고히 하고 있습니다.

용도별로는 암 진단, 바이오마커 동정 및 표적 치료제 개발 분야에서 NGS 기술의 채택 확대에 힘입어, 예측 기간 동안 종양학 분야가 가장 빠른 성장세를 보일 것으로 전망됩니다. NGS를 통해 종양 유전체의 종합적인 프로파일링이 가능해짐에 따라, 임상의가 치료에 활용할 수 있는 돌연변이를 특정하고, 개인 맞춤형 치료법을 선택하는 데 도움이 됩니다. 암 유병률 증가, 정밀 종양학 프로그램의 확대, 그리고 동반 진단의 활용 확대가 이 분야의 성장을 가속화하고 있습니다. 또한, 암 치료제 개발을 위한 시퀀싱 기업과 제약사의 제휴, 그리고 액체 생검 및 유전체 기반 암 모니터링의 발전이 이 부문의 급속한 성장을 더욱 뒷받침할 것으로 예측됩니다.

지역별 개요

2025년, 북미는 차세대 시퀀싱(NGS) 시장을 주도했습니다. 이는 선진적인 의료 인프라, 강력한 유전체 연구 역량, 그리고 제약 기업, 생명공학 기업, 학술 기관의 막대한 투자에 힘입은 결과입니다. 미국은 종양학, 정밀 의학, 유전자 진단, 신약 개발 분야에서의 NGS 광범위한 도입으로 인해 계속해서 가장 큰 기여를 하는 국가로 자리매김하고 있습니다. 주요 시퀀싱 기술 제공업체의 존재, 확립된 연구 네트워크, 유리한 보험 환급 체계, 그리고 유전체 이니셔티브에 대한 지속적인 정부 자금 지원이 이 지역 수요를 더욱 강화하고 있습니다. 또한, 임상 워크플로우 및 맞춤형 의료 프로그램에 NGS가 통합되는 추세가 가속화되면서 북미의 선도적 입지가 더욱 공고해지고 있습니다.

아시아태평양은 의료 분야에 대한 투자 증가, 생명공학 생태계의 확대, 그리고 유전체 기술의 채택 확대에 힘입어, 예측 기간 동안 차세대 시퀀싱(NGS) 시장에서 가장 빠른 성장을 기록할 것으로 예측됩니다. 중국, 일본, 인도 등 국가에서는 정밀의료, 암 유전체학, 농업 유전체학 응용 분야에서 급속한 발전이 나타나고 있습니다. 정부 주도의 유전체 이니셔티브, 연구 협력 확대, 시퀀싱 인프라에 대한 투자 증가가 해당 지역 전체 시장 확대를 가속화하고 있습니다. 또한, 만성 질환 유병률 증가, 의료 접근성 개선, 국내 시퀀싱 기업의 부상으로 인해 아시아 신흥 경제국에서 NGS 도입을 위한 큰 기회가 창출되고 있습니다.

주요 동향 및 성장 촉진요인

인공지능(AI)과 첨단 바이오인포매틱스의 통합 :

차세대 시퀀싱(NGS) 시장에서는 유전체 데이터의 분석 및 해석을 강화하기 위해 인공지능(AI), 머신러닝, 그리고 첨단 바이오인포매틱스 솔루션의 도입이 점점 더 확대되고 있습니다. NGS 플랫폼이 방대한 양의 복잡한 시퀀싱 데이터를 생성하는 가운데, AI를 활용한 도구는 변이 감지, 유전체 어노테이션, 예측 분석의 정확도를 향상시켜 보다 신속하고 정확한 인사이트를 얻을 수 있게 해줍니다. 이러한 진보는 워크플로우의 효율화와 분석 복잡성 감소를 통해 임상 진단, 신약 개발 및 정밀 의학 분야의 응용을 뒷받침하고 있습니다. AI와 NGS 기술의 지속적인 통합으로 혁신이 가속화되고, 의료 및 연구 분야 전반에 걸쳐 시퀀싱 솔루션의 도입이 확대될 것으로 예측됩니다.

정밀 의학 및 유전체 진단 확산 :

정밀 의학 및 유전체 진단의 채택 확대는 차세대 시퀀싱(NGS) 시장의 주요 성장 요인이 되고 있습니다. NGS는 유전적 변이의 종합적인 분석을 가능하게 하여, 맞춤형 치료 전략, 암 프로파일링, 희귀질환 진단 및 약리유전학에 대한 응용을 지원하고 있습니다. 의료 제공업체와 제약 기업은 치료 성과 향상 및 표적 약물 개발 가속화를 위해 시퀀싱 기술을 점점 더 많이 활용하고 있습니다. 만성 질환 유병률 증가, 유전체 연구 프로그램에 대한 투자 확대, 그리고 시퀀싱 기반 진단이 임상 워크플로우에 통합되는 추세의 가속화가 시장 확장을 더욱 뒷받침하고 있습니다. 맞춤형 의료로의 전환에 따라 전 세계적으로 첨단 NGS 솔루션에 대한 강력한 수요가 지속적으로 창출되고 있습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문별 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 회사 소개

KTH 26.08.20

The global Next Generation Sequencing Market is projected to grow from $16.1 billion in 2025 to $46.1 billion by 2035, at a compound annual growth rate (CAGR) of 11.1%. The Next Generation Sequencing Market is characterized by a moderately consolidated structure, with sequencing services and sequencing platforms representing the leading segments due to increasing adoption across clinical diagnostics, oncology, drug discovery, and genomic research. The market is driven by declining sequencing costs, technological advancements, and rising demand for precision medicine. Competitive intensity remains high, with major players such as Illumina, Thermo Fisher Scientific, and BGI Group focusing on innovation, partnerships, and portfolio expansion. For instance, in January 2025, Illumina announced a collaboration with NVIDIA to combine sequencing technologies with AI tools for advancing multiomic data analysis and precision health applications.

Based on Type, the Whole Genome Sequencing segment dominated the Next Generation Sequencing Market in 2025, owing to its ability to provide comprehensive genomic insights by analyzing the complete DNA sequence of an organism. Whole genome sequencing is widely adopted across clinical research, rare disease diagnosis, precision medicine, oncology studies, and population genomics due to its high-resolution data generation capability. The segment benefits from declining sequencing costs, improved bioinformatics platforms, and increasing investments in large-scale genomic initiatives. Growing adoption among academic institutions, pharmaceutical companies, and healthcare providers for identifying genetic variations and supporting personalized treatment strategies further reinforces its leading position in the market.

Market Segmentation
TypeWhole Genome Sequencing, Targeted Sequencing, Exome Sequencing, RNA Sequencing, De Novo Sequencing, Epigenomics, Metagenomics, Others
ProductConsumables, Instruments, Software, Others
ServicesSequencing Services, Data Analysis Services, Others
TechnologySequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Others
ComponentSample Preparation, Sequencing, Data Analysis, Others
ApplicationClinical Investigation, Oncology, Reproductive Health, Agrigenomics, Forensics, Drug Discovery, Others
ProcessLibrary Preparation, Sequencing, Data Processing, Others
End UserAcademic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others
SolutionsIn-House, Outsourced, Others

Based on Application, the Oncology segment is expected to register the fastest growth during the forecast period, driven by the increasing adoption of NGS technologies in cancer diagnosis, biomarker identification, and targeted therapy development. NGS enables comprehensive profiling of tumor genomes, helping clinicians identify actionable mutations and select personalized treatment approaches. The rising prevalence of cancer, expansion of precision oncology programs, and growing use of companion diagnostics are accelerating segment growth. Additionally, collaborations between sequencing companies and pharmaceutical firms for oncology drug development, along with advancements in liquid biopsy and genomic-based cancer monitoring, are expected to further support the rapid expansion of this segment.

Geographical Overview

North America dominated the Next Generation Sequencing (NGS) Market in 2025, supported by advanced healthcare infrastructure, strong genomic research capabilities, and significant investments from pharmaceutical, biotechnology, and academic institutions. The United States remains the leading contributor due to widespread adoption of NGS in oncology, precision medicine, genetic diagnostics, and drug discovery applications. The presence of major sequencing technology providers, well-established research networks, favorable reimbursement frameworks, and continuous government funding for genomics initiatives further strengthens regional demand. Additionally, increasing integration of NGS into clinical workflows and personalized healthcare programs continues to reinforce North America's leading position.

Asia-Pacific is expected to register the fastest growth in the Next Generation Sequencing (NGS) Market during the forecast period, driven by increasing healthcare investments, expanding biotechnology ecosystems, and rising adoption of genomic technologies. Countries such as China, Japan, and India are witnessing rapid development in precision medicine, cancer genomics, and agricultural genomics applications. Government-led genome initiatives, growing research collaborations, and increasing investments in sequencing infrastructure are accelerating market expansion across the region. Furthermore, the rising prevalence of chronic diseases, improving healthcare access, and the growing presence of domestic sequencing companies are creating significant opportunities for NGS adoption in emerging Asian economies.

Key Trends and Drivers

Integration of Artificial Intelligence and Advanced Bioinformatics:

The Next Generation Sequencing (NGS) Market is increasingly adopting artificial intelligence (AI), machine learning, and advanced bioinformatics solutions to enhance genomic data analysis and interpretation. As NGS platforms generate large volumes of complex sequencing data, AI-driven tools are improving variant detection, genome annotation, and predictive analytics, enabling faster and more accurate insights. These advancements are supporting applications in clinical diagnostics, drug discovery, and precision medicine by improving workflow efficiency and reducing analysis complexity. The continued integration of AI with NGS technologies is expected to accelerate innovation and expand the adoption of sequencing solutions across healthcare and research sectors.

Growing Adoption of Precision Medicine and Genomic Diagnostics:

The increasing adoption of precision medicine and genomic diagnostics is a major growth driver for the Next Generation Sequencing (NGS) Market. NGS enables comprehensive analysis of genetic variations, supporting personalized treatment strategies, cancer profiling, rare disease diagnosis, and pharmacogenomics applications. Healthcare providers and pharmaceutical companies are increasingly leveraging sequencing technologies to improve treatment outcomes and accelerate targeted drug development. Rising prevalence of chronic diseases, growing investments in genomic research programs, and increasing integration of sequencing-based diagnostics into clinical workflows are further supporting market expansion. The shift toward personalized healthcare continues to create strong demand for advanced NGS solutions globally.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Whole Genome Sequencing
    • 4.1.2 Targeted Sequencing
    • 4.1.3 Exome Sequencing
    • 4.1.4 RNA Sequencing
    • 4.1.5 De Novo Sequencing
    • 4.1.6 Epigenomics
    • 4.1.7 Metagenomics
    • 4.1.8 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Consumables
    • 4.2.2 Instruments
    • 4.2.3 Software
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Sequencing Services
    • 4.3.2 Data Analysis Services
    • 4.3.3 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Sequencing by Synthesis
    • 4.4.2 Ion Semiconductor Sequencing
    • 4.4.3 Single-Molecule Real-Time Sequencing
    • 4.4.4 Nanopore Sequencing
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Clinical Investigation
    • 4.5.2 Oncology
    • 4.5.3 Reproductive Health
    • 4.5.4 Agrigenomics
    • 4.5.5 Forensics
    • 4.5.6 Drug Discovery
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Academic & Research Institutions
    • 4.6.2 Pharmaceutical & Biotechnology Companies
    • 4.6.3 Hospitals & Clinics
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Sample Preparation
    • 4.7.2 Sequencing
    • 4.7.3 Data Analysis
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Library Preparation
    • 4.8.2 Sequencing
    • 4.8.3 Data Processing
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 In-House
    • 4.9.2 Outsourced
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Roche
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Qiagen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Agilent Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Pacific Biosciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Oxford Nanopore Technologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 BGI Genomics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 PerkinElmer
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bio-Rad Laboratories
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Genewiz
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Takara Bio
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 10x Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 F. Hoffmann-La Roche
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Eurofins Scientific
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Macrogen
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Genomatix
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 GATC Biotech
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 LGC Biosearch Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Nugen Technologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기